Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Express Scripts
Moodys
AstraZeneca
Mallinckrodt

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Patent: 8,231,895

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,231,895
Title:Targeted delivery to human diseases and disorders
Abstract: The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.
Inventor(s): de Almeida Moreira; Joao Nuno Sereno (Coimbra, PT), Caldeira de Moura; Vera L cia Dantas Nunes (Coimbra, PT), de Magalhaes Simoes; Sergio Paulo (Coimbra, PT), Pedroso de Lima; Maria da Conceicao Monteiro (Coimbra, PT)
Assignee: Universidade de Coimbra (Coimbra, PT) Centro de Neurociencias e Biologia Celular (Coimbra, PT)
Application Number:12/153,649
Patent Claims:see list of patent claims

Details for Patent 8,231,895

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Try it Free 2039-02-26
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Try it Free 2039-02-26
Genentech, Inc. AVASTIN bevacizumab Injection 125085 2004-02-26 ⤷  Try it Free 2039-02-26
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 2019-02-28 ⤷  Try it Free 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
McKinsey
Baxter
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.